Progress in new drug research and development of thrombopoietin receptor agonists against immune thrombocytopenia
ZHANG Ke
LEI Hui
CHEN Xi
ZHAO Xin
SUN Yi
PU Xiao-ping
Abstract：Immune thrombocytopenia (ITP) is an acquired common hemorrhagic condition characterized by a low platelet count and hemorrhage,which is caused by excessive platelet destruction and thrombopoiesis deficiency.Clinical therapy includes pharmacotherapy with corticosteroids and immunosuppressants and surgical treatment of splenectomy in order to reduce the destruction of platelets.With the deep understanding of the pathogenesis and etiology of ITP,thrombopoietin receptor agonists (TPO-RAs,TRAs) become a new way of ITP treatment,which increases platelet production by stimulating megakaryocytes.In this article,the status of research and development of TRAs for the treatment of ITP is reviewed.
Keywords：immune thrombocytopeniathrombopoietinthrombopoietin receptor agonists
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 2380-2385 )